Technical Analysis for IFRX - InflaRx N.V.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | -3.23% | |
| New 52 Week Closing Low | Bearish | -3.23% | |
| Lower Bollinger Band Touch | Weakness | -3.23% | |
| 20 DMA Resistance | Bearish | -7.34% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -7.34% |
| Alert | Time |
|---|---|
| Down 5% | about 15 hours ago |
| Down 3% | about 15 hours ago |
| Fell Below Previous Day's Low | about 15 hours ago |
| 60 Minute Opening Range Breakdown | about 15 hours ago |
| Fell Below Lower Bollinger Band | about 15 hours ago |
Get a Trading Sidekick!
- Earnings date: 06/05/2024
InflaRx N.V. Description
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Immunology Immune System Clinical Development Antibodies Autoimmune Disease Monoclonal Antibodies Monoclonal Antibody Inflammatory Diseases Complement System Hidradenitis Suppurativa C5a
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.2 |
| 52 Week Low | 1.14 |
| Average Volume | 206,753 |
| 200-Day Moving Average | 2.13 |
| 50-Day Moving Average | 1.51 |
| 20-Day Moving Average | 1.35 |
| 10-Day Moving Average | 1.34 |
| Average True Range | 0.13 |
| RSI (14) | 32.89 |
| ADX | 13.9 |
| +DI | 8.65 |
| -DI | 17.98 |
| Chandelier Exit (Long, 3 ATRs) | 1.27 |
| Chandelier Exit (Short, 3 ATRs) | 1.55 |
| Upper Bollinger Bands | 1.51 |
| Lower Bollinger Band | 1.20 |
| Percent B (%b) | 0.01 |
| BandWidth | 23.29 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.05 |
| MACD Histogram | -0.0083 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.39 | ||||
| Resistance 3 (R3) | 1.40 | 1.34 | 1.36 | ||
| Resistance 2 (R2) | 1.34 | 1.30 | 1.34 | 1.35 | |
| Resistance 1 (R1) | 1.27 | 1.27 | 1.25 | 1.26 | 1.34 |
| Pivot Point | 1.22 | 1.22 | 1.21 | 1.21 | 1.22 |
| Support 1 (S1) | 1.15 | 1.17 | 1.12 | 1.14 | 1.06 |
| Support 2 (S2) | 1.09 | 1.14 | 1.09 | 1.05 | |
| Support 3 (S3) | 1.02 | 1.09 | 1.04 | ||
| Support 4 (S4) | 1.01 |
